Top Markets
#1 Doge Strategy Doge Strategy +1,105,414.43%
#2 Noon Noon +10,549.79%
#3 Siren Siren +110.82%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +43.50%
#6 Gigachad Gigachad +25.48%
#7 Ontology Ontology +20.07%
#8 TRIA TRIA +18.98%
#9 Echelon Prime Echelon Prime +18.98%
#10 Win Win +17.98%
Coin of the day
Doge Strategy Doge Strategy
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Classificação em ações #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Preço da ação
$0.0416118
Valor de mercado
$12.78M
Variação (1 dia)
1.72%
Variação (1 ano)
-22.01%
País
AU
Negociar Noxopharm Limited (NOX)

Categoria

Healthcare
Lucros da Noxopharm Limited (NOX)
Lucros em Dec 2025 TTM: $-4.82M
De acordo com os últimos relatórios financeiros da Noxopharm Limited, os ganhos atuais da empresa são de $-4.82M. Em 2024, a empresa teve ganhos de $-3.99M, um aumento em relação a aos ganhos de 2023, que foram de $-14.02M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Noxopharm Limited de 2016 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $-4.82M 49.79%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -424,852.71%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -96,506.98%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -108,705.27%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -44,485.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -33,617.45%
AU